Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048704663> ?p ?o ?g. }
- W3048704663 abstract "Abstract Background This study was an open-label, 2-arms, monocentric, randomized clinical trial comparing Xonrid®, a topical medical device, versus standard of care (SOC) in preventing and treating acute radiation dermatitis (ARD) in Head and Neck Cancer (HNC) and Breast Cancer (BC) patients undergoing radiotherapy (RT). Methods Eligible HNC and BC patients were randomized 1:1 to receive Xonrid® + SOC or SOC during RT. Patients were instructed to apply Xonrid® on the irradiated area three times daily, starting on the first day of RT and until 2 weeks after RT completion or until the development of grade ≥ 3 skin toxicity. The primary endpoint was to evaluate the proportion of patients who developed an ARD grade < 2 at the 5th week in both groups. Secondary endpoints were median time to grade 2 (G2) skin toxicity onset; changes in skin erythema and pigmentation and trans-epidermal water loss (TEWL); patient-reported skin symptoms. All patients were evaluated at baseline, weekly during RT and 2 weeks after treatment completion. The evaluation included: clinical toxicity assessment; reflectance spectrometry (RS) and TEWL examination; measurement of patients’ quality of life (QoL) through Skindex-16 questionnaire. Results Eighty patients (40 for each cancer site) were enrolled between June 2017 and July 2018. Groups were well balanced for population characteristics. All BC patients underwent 3-Dimensional Conformal RT (3D-CRT) whereas HNC patients underwent Volumetric-Modulated Arc Therapy (VMAT). At week 5 the proportion of BC patients who did not exhibit G2 ARD was higher in Xonrid® + SOC group ( p = 0.091). In the same group the onset time of G2 ARD was significantly longer than in SOC-alone group ( p < 0.0491). For HNC groups there was a similar trend, but it did not reach statistical significance. For both cancer sites, patients’ QoL, measured by the Skindex-16 score, was always lower in the Xonrid® + SOC group. Conclusion Despite the failure to achieve the primary endpoint, this study suggests that Xonrid® may represent a valid medical device in the prevention and treatment of ARD at least in BC patients, delaying time to develop skin toxicity and reducing the proportion of patients who experienced G2 ARD during RT treatment and 2 weeks later. Trial registration The study was approved by the Ethical Committee of Fondazione IRCCS Istituto Nazionale dei Tumori di Milano (INT 52/14 - NCT02261181 ). Registered on ClinicalTrial.gov on 21st August 2017." @default.
- W3048704663 created "2020-08-18" @default.
- W3048704663 creator A5002383005 @default.
- W3048704663 creator A5003845504 @default.
- W3048704663 creator A5010124917 @default.
- W3048704663 creator A5014239599 @default.
- W3048704663 creator A5018624121 @default.
- W3048704663 creator A5020292824 @default.
- W3048704663 creator A5026618047 @default.
- W3048704663 creator A5029235673 @default.
- W3048704663 creator A5029417500 @default.
- W3048704663 creator A5041270170 @default.
- W3048704663 creator A5042175999 @default.
- W3048704663 creator A5046867654 @default.
- W3048704663 creator A5052156214 @default.
- W3048704663 creator A5064894022 @default.
- W3048704663 creator A5067540429 @default.
- W3048704663 creator A5069750407 @default.
- W3048704663 creator A5070422496 @default.
- W3048704663 creator A5075219078 @default.
- W3048704663 creator A5081945327 @default.
- W3048704663 creator A5083335271 @default.
- W3048704663 creator A5085160524 @default.
- W3048704663 creator A5087783156 @default.
- W3048704663 date "2020-08-13" @default.
- W3048704663 modified "2023-10-01" @default.
- W3048704663 title "A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients" @default.
- W3048704663 cites W1968822573 @default.
- W3048704663 cites W1997179621 @default.
- W3048704663 cites W1999075599 @default.
- W3048704663 cites W2004020565 @default.
- W3048704663 cites W2009262068 @default.
- W3048704663 cites W2022506986 @default.
- W3048704663 cites W2027214733 @default.
- W3048704663 cites W2050807296 @default.
- W3048704663 cites W2053860026 @default.
- W3048704663 cites W2073694682 @default.
- W3048704663 cites W2089257078 @default.
- W3048704663 cites W2096499183 @default.
- W3048704663 cites W2104143997 @default.
- W3048704663 cites W2148505042 @default.
- W3048704663 cites W2169409973 @default.
- W3048704663 cites W2169449140 @default.
- W3048704663 cites W2578386622 @default.
- W3048704663 cites W2737448536 @default.
- W3048704663 cites W2766795734 @default.
- W3048704663 cites W2770564178 @default.
- W3048704663 cites W2789698864 @default.
- W3048704663 cites W2792882552 @default.
- W3048704663 cites W2807323488 @default.
- W3048704663 cites W2895282658 @default.
- W3048704663 cites W2896609964 @default.
- W3048704663 cites W2903110660 @default.
- W3048704663 cites W2917693241 @default.
- W3048704663 cites W2918685113 @default.
- W3048704663 cites W2947414727 @default.
- W3048704663 cites W2953854859 @default.
- W3048704663 cites W3010864066 @default.
- W3048704663 doi "https://doi.org/10.1186/s13014-020-01633-0" @default.
- W3048704663 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7427075" @default.
- W3048704663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32791985" @default.
- W3048704663 hasPublicationYear "2020" @default.
- W3048704663 type Work @default.
- W3048704663 sameAs 3048704663 @default.
- W3048704663 citedByCount "8" @default.
- W3048704663 countsByYear W30487046632022 @default.
- W3048704663 countsByYear W30487046632023 @default.
- W3048704663 crossrefType "journal-article" @default.
- W3048704663 hasAuthorship W3048704663A5002383005 @default.
- W3048704663 hasAuthorship W3048704663A5003845504 @default.
- W3048704663 hasAuthorship W3048704663A5010124917 @default.
- W3048704663 hasAuthorship W3048704663A5014239599 @default.
- W3048704663 hasAuthorship W3048704663A5018624121 @default.
- W3048704663 hasAuthorship W3048704663A5020292824 @default.
- W3048704663 hasAuthorship W3048704663A5026618047 @default.
- W3048704663 hasAuthorship W3048704663A5029235673 @default.
- W3048704663 hasAuthorship W3048704663A5029417500 @default.
- W3048704663 hasAuthorship W3048704663A5041270170 @default.
- W3048704663 hasAuthorship W3048704663A5042175999 @default.
- W3048704663 hasAuthorship W3048704663A5046867654 @default.
- W3048704663 hasAuthorship W3048704663A5052156214 @default.
- W3048704663 hasAuthorship W3048704663A5064894022 @default.
- W3048704663 hasAuthorship W3048704663A5067540429 @default.
- W3048704663 hasAuthorship W3048704663A5069750407 @default.
- W3048704663 hasAuthorship W3048704663A5070422496 @default.
- W3048704663 hasAuthorship W3048704663A5075219078 @default.
- W3048704663 hasAuthorship W3048704663A5081945327 @default.
- W3048704663 hasAuthorship W3048704663A5083335271 @default.
- W3048704663 hasAuthorship W3048704663A5085160524 @default.
- W3048704663 hasAuthorship W3048704663A5087783156 @default.
- W3048704663 hasBestOaLocation W30487046631 @default.
- W3048704663 hasConcept C121608353 @default.
- W3048704663 hasConcept C126322002 @default.
- W3048704663 hasConcept C141071460 @default.
- W3048704663 hasConcept C159110408 @default.
- W3048704663 hasConcept C168563851 @default.
- W3048704663 hasConcept C203092338 @default.
- W3048704663 hasConcept C2776530083 @default.
- W3048704663 hasConcept C2779121184 @default.
- W3048704663 hasConcept C2779951463 @default.